Leukaemia Treatment in India – Chemotherapy, Targeted Therapy & BMT
Leukaemia treatment in India from $8,000. Expert haematology-oncology for ALL, AML, CLL, CML. Chemotherapy, targeted therapy, CAR-T, and stem-cell transplant at top NABH hospitals.
Estimated cost: $8,000 – $40,000 · Average stay: 21–60 days
Leukaemia is a cancer of the blood and bone marrow in which abnormal white blood cells multiply uncontrollably, crowding out normal blood cells. The four main types — ALL, AML, CLL, and CML — have distinct biological profiles and require different treatment approaches.
India's haematology-oncology centres offer the full leukaemia treatment spectrum: from induction chemotherapy to targeted therapy with tyrosine kinase inhibitors, monoclonal antibodies, CAR-T cell therapy, and haematopoietic stem-cell transplantation — all at 70–90% lower cost than the US or UK.
Generic imatinib for CML costs $100–$300/month in India versus over $10,000/month in the US. Tata Memorial Hospital, CMC Vellore, AIIMS Delhi, and Apollo Hospitals are globally recognised leukaemia treatment centres with internationally benchmarked outcomes.
What is Leukaemia?
Leukaemia arises from mutations in early blood cell precursors in the bone marrow. Acute leukaemias (ALL, AML) present rapidly with bone marrow failure — anaemia, bleeding, infections — and require urgent treatment. Chronic leukaemias (CML, CLL) have a more indolent course, often discovered incidentally, but require long-term management.
CML is driven by the BCR-ABL1 oncogene and responds dramatically to oral tyrosine kinase inhibitors (TKIs). ALL is treated with multi-drug induction-consolidation-maintenance protocols. AML requires intensive chemotherapy with stem-cell transplant in high-risk cases. CLL is treated with targeted agents (ibrutinib, venetoclax) or chemo-immunotherapy based on genomic risk profile.
Who Can Be Treated for Leukaemia in India?
All leukaemia types are treated in India. New diagnoses benefit most from India's combination of expert haematology-oncology teams and dramatically lower treatment costs — particularly for CML (where lifelong TKI therapy is unaffordable in many countries) and ALL in children (where 90%+ cure rates are achievable). International patients with relapsed/refractory leukaemia benefit from access to CAR-T therapy and innovative clinical trials at India's premier cancer centres.
How is Leukaemia Treated in India?
Diagnosis involves bone marrow aspirate and biopsy, immunophenotyping by flow cytometry, cytogenetics (karyotype and FISH), and molecular testing (BCR-ABL1 for CML, FLT3/NPM1/IDH1/2 for AML). Treatment is risk-stratified.
CML: oral TKI (imatinib/dasatinib/nilotinib) with quarterly BCR-ABL1 molecular monitoring. ALL: multi-drug induction (vincristine, prednisolone, asparaginase, daunorubicin) followed by consolidation, CNS prophylaxis, and 2-year maintenance. AML: intensive 7+3 induction, consolidation, and allogeneic SCT in high-risk cases. CLL: ibrutinib-venetoclax or FCR based on IGHV/TP53 status. CAR-T cell therapy is available for relapsed/refractory ALL and CLL at leading Indian centres.
Procedure Steps
- Bone marrow aspirate and biopsy; peripheral blood immunophenotyping by flow cytometry
- Cytogenetics: karyotype, FISH for BCR-ABL, MLL, and disease-specific rearrangements
- Molecular testing: BCR-ABL1, FLT3, NPM1, IDH1/2, TP53 mutation panel
- Lumbar puncture for CNS disease assessment in ALL and high-risk AML
- Risk stratification: standard, high, or very-high risk protocol selection
- CML: TKI initiation; BCR-ABL1 molecular monitoring three-monthly
- ALL induction: vincristine, prednisolone, asparaginase, daunorubicin; day 28 marrow assessment
- AML induction: cytarabine + anthracycline (7+3 protocol)
- Consolidation chemotherapy or allogeneic SCT in high-risk cases
- MRD monitoring by PCR or flow cytometry to guide treatment decisions
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $8,000 – $40,000 — Save 88%
UAE — $80,000 – $300,000 — Save 87%
United States — $200,000 – $800,000 — —
United Kingdom — $100,000 – $400,000 — —
Generic imatinib in India costs $100–$300/month vs $10,000+/month for branded Gleevec in the US. AML induction costs $20,000–$40,000 in India. Allogeneic SCT is priced separately at $25,000–$40,000. India offers leukaemia treatment at 80–95% lower cost than the US with equivalent clinical outcomes.
Recovery & Follow-up
Recovery depends on leukaemia type and treatment phase. CML patients on TKIs maintain normal activity throughout treatment. ALL and AML patients experience significant treatment intensity — fatigue, infection risk, and hospitalisation are expected during induction and consolidation. Recovery of normal blood counts occurs 3–6 weeks after induction chemotherapy.
Recovery Tips
- Take TKI medications at the same time each day and never stop without medical advice.
- During intensive chemotherapy, follow strict infection prevention: wash hands frequently, avoid sick contacts.
- Maintain a balanced diet with adequate protein to support bone marrow recovery.
- Attend all scheduled bone marrow assessment and MRD monitoring appointments.
- Report any fever above 38°C immediately — neutropenic fever is a medical emergency.
Risks & Complications
Chemotherapy risks include bone marrow suppression (infection, bleeding, anaemia), mucositis, nausea, and hair loss. TKI side effects include fluid retention, rash, fatigue, and cardiac effects (rare). Allogeneic SCT risks include GVHD, infection, and rejection. Long-term risks with cured disease include secondary malignancies and chemotherapy-induced organ damage with close long-term surveillance.
Why GAF Healthcare
Gaf Healthcare facilitates priority access to India's leading haematology-oncology centres, prepares treatment protocol letters for home oncologists, arranges medication supply continuity for oral targeted agents, and coordinates telemedicine follow-up with the Indian haematologist for seamless remote monitoring of treatment response.
Frequently Asked Questions
Which leukaemia types have the best cure rates?
ALL in children has cure rates exceeding 90%. CML treated with TKIs achieves deep molecular remission in 80–90% — many patients may eventually discontinue therapy. AML has variable outcomes but cure is achievable with SCT in favourable-risk cases.
Is generic imatinib for CML available in India?
Yes. Generic imatinib costs $100–$300/month in India versus $10,000+/month for branded Gleevec in the US. Second-generation TKIs (dasatinib, nilotinib) are also available as generics. Long-term CML management is highly affordable.
Is CAR-T cell therapy available in India?
Yes. CAR-T therapy is now available at Tata Memorial, CMC Vellore, and other leading centres for relapsed/refractory ALL and CLL at a fraction of the US cost of $400,000+.
How long is leukaemia treatment in India?
CML requires indefinite oral therapy. ALL treatment lasts 2–3 years. AML requires 4–6 months of intensive therapy plus potential SCT. International patients typically complete the intensive initial phase in India and continue maintenance at home.
Can I continue leukaemia treatment in my home country after starting in India?
Yes. We prepare detailed protocol letters for your home oncologist and arrange medication supply continuity, especially for oral targeted agents. Telemedicine follow-up with the Indian haematologist ensures seamless treatment oversight.